Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06013865 · ClinicalTrials.gov registry record · Phase 4
Empagliflozin Treatment in Kidney Transplant Recipients
A Phase 4 study of Chronic Kidney Disease and Kidney Transplant, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 264
- Enrollment target
- 5
- Study locations
NCT06013865 is a Phase 4 study of Chronic Kidney Disease and Kidney Transplant that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 264 participants, below the 3,204-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT06013865, a Phase 4 study of Chronic Kidney Disease and Kidney Transplant, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 264 participants
- Enrollment target
- 5
- Study locations
Study Summary
Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging. Patient death with existing kidney graft function occurs in about half of all recipients over time. This is primarily due to the development of cardiovascular disease in a patient population with multiple preexisting cardiac disease risk factors. There has been little progress in improving outcomes in this area for over two decades. Recent studies in chronic kidney disease (CKD) patients using SGLT2 inhibitors (SGLT2i), regardless of the presence of type 2 diabetes mellitus (T2DM), results in both kidney protective and cardiac protective impacts and improved patient outcomes. However, kidney transplant recipients (KTRs) were excluded from these clinical trials due to concerns that these agents promote infection, diminish graft function, and may alter immunosuppressive drug levels that are the mainstay of patient's transplant therapy. There are limited published data of SGLT2i treatment of selected KTRs.
Conditions Studied
Interventions
- DRUG Empagliflozin
Study Locations (5)
Illinois
- Edward Hines Jr. VA Hospital, Hines, IL - Hines
Iowa
- Iowa City VA Health Care System, Iowa City, IA - Iowa City
Nebraska
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE - Omaha
Pennsylvania
- VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA - Pittsburgh
Tennessee
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TN - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2024-04-05 |
| Est. Completion | 2030-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06013865
The ClinicalTrials.gov registry entry for NCT06013865 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,204-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (92% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Empagliflozin is the first listed.
NCT06013865 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Iowa, Nebraska.
Frequently Asked Questions
What is clinical trial NCT06013865 about?
NCT06013865 is a clinical study titled "Empagliflozin Treatment in Kidney Transplant Recipients". Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging. Patient death with existing kidney graft function occurs in about half of all r...
What is the current status of trial NCT06013865?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 264 participants. The study started on 2024-04-05. Estimated completion is 2030-03-31.
What conditions does trial NCT06013865 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, Kidney Transplant.
What interventions are being tested in trial NCT06013865?
The interventions under investigation include: Empagliflozin (DRUG).
Who is sponsoring clinical trial NCT06013865?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06013865 being conducted?
This trial has 5 study locations across Illinois, Iowa, Nebraska, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety of Short-course of NSAIDs in Pediatric Patients With CKD
RECRUITING · Phase 4
-
L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients
RECRUITING · Phase 4
-
Trial to Optimize Mineral Outcomes in Dialysis Patients
COMPLETED · Phase 4
-
Phosphate Lowering in CKD Trial
COMPLETED · Phase 4
-
A Chronic Care Model Based Quality Improvement (QI) Program to Improve the Care of Patients With Chronic Kidney Disease (CKD)
COMPLETED · Phase 4
-
Dialysis Clinical Outcomes Revisited (DCOR) Trial
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.